AR041376A1 - Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia - Google Patents
Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofreniaInfo
- Publication number
- AR041376A1 AR041376A1 ARP030103476A ARP030103476A AR041376A1 AR 041376 A1 AR041376 A1 AR 041376A1 AR P030103476 A ARP030103476 A AR P030103476A AR P030103476 A ARP030103476 A AR P030103476A AR 041376 A1 AR041376 A1 AR 041376A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- atoms
- ring
- substituents
- Prior art date
Links
- 125000001153 fluoro group Chemical group F* 0.000 abstract 9
- -1 1,2-benzisoxazoyl Chemical group 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 abstract 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 abstract 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000005956 isoquinolyl group Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000004885 piperazines Chemical group 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000005493 quinolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente se refiere a piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia, a composiciones farmacéuticas que los contienen, y a su uso en el tratamiento de trastornos del sistema nervioso central. Reivindicación 1:Un compuesto de fórmula (1), caracterizado porque Ar es 1,2-bencisotiazoilo, 1,2-bencisotiazoil-1-óxido, 1,2-bencisotiazoil-1-dióxido, 1,2-bencisoxazoilo, naftilo, piridilo, quinolilo, isoquinolilo, benzotiadiazolilo, benzotriazolilo, benzoxazolilo,benzoxazolonilo, ftalacinilo, indolilo, indanilo, 1H-indazoilo o 3-indazolilo, y en la que Ar puede estar opcionalmente sustituido con uno o más sustituyentes, preferiblemente de 0 a 4 sustituyentes, independientemente seleccionados de halógeno,preferiblemente cloro o flúor, ciano, nitro, alquilo (C1-6) opcionalmente sustituido con 1 a 3 átomos de F, y alcoxi (C1-6) opcionalmente sustituido con 1 a 3 átomos de F; con la condición de que Ar no puede estar unido al anillo de piperazina porun anillo de fenilo de Ar; Y es N o CH; A es -(CH2)nCH2-, en el que n es un número entero de 1 a 4, en el que uno de los grupos CH2 que no es adyacente al N de la piperazina se puede sustituir opcionalmente por un átomo de O; R2 y R3 se seleccionanindependientemente de H, alquilo (C1-6) opcionalmente sustituido con 1 a 3 átomos de F, alcoxi (C1-6) opcionalmente sustituido con 1 a 3 átomos de F, halógeno, nitro, ciano, amino, alquil (C1-6)-amino, y di-alquil(C1-6)-amino; y el anillo Q pude serun anillo heterocíclico monocíclico de 5 a 7 miembros saturado, insaturado o aromático, que contiene de 1 a 3 heteroátomos independientemente seleccionados de O, N y S, y en la que Q puede estar opcionalmente sustituido con 1 a 4 sustituyentes,preferiblemente con 2 o 3 sustituyentes, independientemente seleccionados de amino, oxo, hidroxi, alquilo (C1-6) opcionalmente sustituido con 1 a 3 átomos de F, alcoxi (C1-6) opcionalmente sustituido con 1 a 3 átomos de F, arilo, aril-alquilo(C1-6),alquenilo (C1-6) opcionalmente sustituido con 1 a 3 átomos de F, heteroarilo y heteroaril-alquilo(C1-6), en los que los restos alquilo de los grupos aril-alquilo(C1-6) y heteroaril-alquilo(C1-6) pueden estar opcionalmente sustituidos con 1 a 3átomos de F, y donde los restos arilo y heteroarilo de estos grupos pueden estar opcionalmente sustituidos con uno o más sustituyentes, preferiblemente de 0 a 2 sustituyentes, independientemente seleccionados de halógeno, oxo, nitro, amino, ciano,alquilo(C1-6) opcionalmente sustituido con 1 a 3 átomos de F, y alcoxi(C1-6) opcionalmente sustituido con 1 a 3 átomos de F; y en la que uno de los sustituyentes en el anillo Q puede ser una cadena de alquilo que forma un anillo espirocíclico de 3 a6 miembros con un átomo de C del anillo Q que no es adyacente a un heteroátomo del anillo Q; con la condición de que no puede haber más de un sustituyente oxo en el anillo Q y no puede haber más de un sustituyente alquilo espirocíclico en el anilloQ; o una de sus sales farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41383902P | 2002-09-26 | 2002-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041376A1 true AR041376A1 (es) | 2005-05-11 |
Family
ID=32043299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103476A AR041376A1 (es) | 2002-09-26 | 2003-09-24 | Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20040067960A1 (es) |
| EP (1) | EP1546145A1 (es) |
| JP (1) | JP2006503846A (es) |
| AR (1) | AR041376A1 (es) |
| AU (1) | AU2003260882A1 (es) |
| BR (1) | BR0314796A (es) |
| CA (1) | CA2500115A1 (es) |
| GT (1) | GT200300212A (es) |
| MX (1) | MXPA05002003A (es) |
| PA (1) | PA8583801A1 (es) |
| PE (1) | PE20050133A1 (es) |
| TW (1) | TW200413363A (es) |
| UY (1) | UY27998A1 (es) |
| WO (1) | WO2004029048A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1562919A1 (en) * | 2002-11-08 | 2005-08-17 | Warner-Lambert Company LLC | Phenylalkyl and pyridylalkyl piperazine derivatives |
| EP1697334A1 (en) * | 2003-12-08 | 2006-09-06 | Warner-Lambert Company LLC | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia |
| WO2006090273A2 (en) * | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| AR055203A1 (es) | 2005-08-31 | 2007-08-08 | Otsuka Pharma Co Ltd | Derivados de benzotiofeno con propiedades antipsicoticas |
| US20080186971A1 (en) * | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| US20090076028A1 (en) * | 2007-09-15 | 2009-03-19 | Protia, Llc | Deuterium-enriched itraconazole |
| US20090076027A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched lurasidone |
| US20090082363A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched posaconazole |
| US20110160253A1 (en) * | 2008-05-28 | 2011-06-30 | Harbeson Scott L | Deuterated tizanidine |
| JP5714152B2 (ja) * | 2014-03-26 | 2015-05-07 | 江蘇恒誼薬業有限公司 | アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用 |
| US10160778B2 (en) * | 2014-10-27 | 2018-12-25 | Concert Pharmaceuticals, Inc. | Pyrimidine phosphonic acid esters |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN115521302B (zh) * | 2022-09-20 | 2025-03-21 | 徐州医科大学 | 一种四氢（异）喹啉或吲哚啉类衍生物、组合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704390A (en) * | 1986-02-13 | 1987-11-03 | Warner-Lambert Company | Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents |
| US5364866A (en) * | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
| US5350747A (en) * | 1989-07-07 | 1994-09-27 | Pfizer Inc | Heteroaryl piperazine antipsychotic agents |
| WO1991000863A1 (en) * | 1989-07-07 | 1991-01-24 | Pfizer Inc. | Heteroaryl piperazine antipsychotic agents |
| NZ240863A (en) * | 1991-09-11 | 1995-04-27 | Mcneilab Inc | Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof |
| US5576321A (en) * | 1995-01-17 | 1996-11-19 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| US6242450B1 (en) * | 1998-07-27 | 2001-06-05 | Eli Lilly And Company | 5-HT1F antagonists |
| ES2244438T3 (es) * | 1999-05-24 | 2005-12-16 | Mitsubishi Pharma Corporation | Compuestos de fenoxipropilamina. |
| CA2426706A1 (en) * | 2000-10-26 | 2002-05-02 | Smithkline Beecham P.L.C. | Benzoxazinone derivatives, their preparation and use |
-
2003
- 2003-09-18 MX MXPA05002003A patent/MXPA05002003A/es unknown
- 2003-09-18 CA CA002500115A patent/CA2500115A1/en not_active Abandoned
- 2003-09-18 WO PCT/IB2003/004113 patent/WO2004029048A1/en not_active Ceased
- 2003-09-18 JP JP2004539333A patent/JP2006503846A/ja not_active Withdrawn
- 2003-09-18 BR BR0314796-7A patent/BR0314796A/pt not_active IP Right Cessation
- 2003-09-18 EP EP03798314A patent/EP1546145A1/en not_active Withdrawn
- 2003-09-18 AU AU2003260882A patent/AU2003260882A1/en not_active Abandoned
- 2003-09-22 PA PA20038583801A patent/PA8583801A1/es unknown
- 2003-09-23 PE PE2003000974A patent/PE20050133A1/es not_active Application Discontinuation
- 2003-09-24 GT GT200300212A patent/GT200300212A/es unknown
- 2003-09-24 AR ARP030103476A patent/AR041376A1/es unknown
- 2003-09-24 UY UY27998A patent/UY27998A1/es not_active Application Discontinuation
- 2003-09-25 TW TW092126485A patent/TW200413363A/zh unknown
- 2003-09-26 US US10/672,949 patent/US20040067960A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040067960A1 (en) | 2004-04-08 |
| UY27998A1 (es) | 2004-04-30 |
| TW200413363A (en) | 2004-08-01 |
| JP2006503846A (ja) | 2006-02-02 |
| BR0314796A (pt) | 2005-07-26 |
| PE20050133A1 (es) | 2005-03-22 |
| WO2004029048A1 (en) | 2004-04-08 |
| EP1546145A1 (en) | 2005-06-29 |
| PA8583801A1 (es) | 2004-05-07 |
| MXPA05002003A (es) | 2005-08-03 |
| CA2500115A1 (en) | 2004-04-08 |
| GT200300212A (es) | 2004-05-25 |
| AU2003260882A1 (en) | 2004-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2500680C2 (ru) | Новые замещенные пиридин-2-оны и пиридазин-3-оны | |
| AR041376A1 (es) | Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| CO5690643A2 (es) | Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos | |
| AR002746A1 (es) | Compuestos derivados de pirimidina condensados con un anillo heterociclico y composicion farmaceutica conteniendo dichos compuestos. | |
| AR044829A1 (es) | Derivados de bis-4-cloro fenil pirazinas | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| AR033306A1 (es) | Compuestos | |
| AR041260A1 (es) | Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR038419A1 (es) | Derivados de piridina y quinolina | |
| AR035892A1 (es) | Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos | |
| CY1107677T1 (el) | Παραγωγα της 1-[indol-3-yl)carbonyl]piperazine | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| SE9702799D0 (sv) | New compounds | |
| AR050261A2 (es) | Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento | |
| AR043700A1 (es) | Derivados de 3-substituida-4-pirimidona | |
| PE20191784A1 (es) | Compuestos inhibidores de vmat2, composiciones y metodos relativos a los mismos | |
| AR018915A1 (es) | Inhibidores de proteasas diacilhidrazinicos, composicion farmaceutica que la comprenden, usos de los mismos para la manufactura de un medicamento, unprocedimiento de fabricacion de dichos compuestos | |
| AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| MX2019008331A (es) | Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos. | |
| AR041898A1 (es) | Derivados de 4(fenil-piperazinil-metil) benzamida y sus usos para el tratamiento del dolor y desordenes gastrointestinales | |
| AR017200A1 (es) | Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |